Blog

Maine plateaus in reduction of antipsychotic use; toolkit coming to move the needle

According to CMS data through Q3 2018, Maine achieved a 35% reduction in the use of antipsychotic medications. Even with improvement, Maine ranks 43rd the country in terms of prevalence. The Maine Partnership to Improve Dementia Care continues working with providers to make further reductions and improvements.
 
CMS is tracking the progress of the Partnership by reviewing publicly reported measures. As a reminder, the official measure of the Partnership is a the percent of long-stay nursing home residents who are receiving an antipsychotic medication, excluding those residents diagnosed with schizophrenia, Huntington's Disease or Tourette's Syndrome. In 2011 Q4, 23.9% of long-stay nursing home residents nationwide were receiving an antipsychotic medication; since then there has been a decrease of 38.9% to a national prevalence of 14.6% in 2018 Q3. Success has varied by state and CMS region.
 
The Partnership continues to work on the Dementia Care Change Package. Members may recall that this framework takes a multi-pronged approach aimed at improving dementia care and decreasing the off-label use of antipsychotics in nursing homes across the state. It includes areas like physician education, data, staff competencies, environmental factors, etc. Facilities that use the toolkit should see a reduction in A/P utilization.
 
The next meeting is: 
 
Tuesday, March 26, 2019, 9:30 am at Maine Health Care Association,
317 State Street, Augusta, ME 04074, Ph: 207-623-1146
 
If you would like to be added to a subcommittee to work on one of the eight parts of the package, or would like to RSVP for the meeting, please contact Nadine Grosso at ngrosso@mehca.org.
 
Staff Contact:
Nadine Grosso, Vice President & Director of Communications
ngrosso@mehca.org